Life Sciences
Executives pointed to faster-than-expected AI adoption in healthcare, shifting regulatory signals and growing demand for AI tools that deliver measurable outcomes.
uMed’s registry platform will work alongside WellSky’s network of home-based care organizations to let patients participate in national clinical trials from home.
The Australian research, which aims to help people with motor neuron disease keep moving, is now testing AI to personalise assistance.
Alongside the acquisition, the two companies entered a multi-year partnership to cross-integrate their platforms, aiming to expand access to clinical trials.
Industry leaders say 2025 marked AI’s shift from hype to practical impact, though the technology remains unready for full-scale adoption and ongoing concerns about ethics and bias persist.
The partners are employing AI to identify undiagnosed and undertreated patients, support clinical trials and advance precision therapies.
Developed by Cancer Institute NSW, the multi-data-trained tool aims to educate people over 40 about their cancer risks.
During a fireside chat with Scripta Insights’ CEO, Cuban discussed TrumpRx and unveiled new MCCPDC innovations, including mobile drug-making pods and the Cost Plus Wellness network.
The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.
The funds will be used to bolster AI and computational physics-based model development for numerous modalities.